KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) Leases (2016 - 2026)

West Pharmaceutical Services has reported Leases over the past 14 years, most recently at $110.2 million for Q1 2026.

  • Quarterly Leases rose 6.58% to $110.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $110.2 million through Mar 2026, up 6.58% year-over-year, with the annual reading at $117.0 million for FY2025, 11.96% up from the prior year.
  • Leases was $110.2 million for Q1 2026 at West Pharmaceutical Services, down from $117.0 million in the prior quarter.
  • Over five years, Leases peaked at $117.0 million in Q4 2025 and troughed at $75.6 million in Q1 2022.
  • The 5-year median for Leases is $101.1 million (2023), against an average of $99.5 million.
  • Biggest five-year swings in Leases: skyrocketed 50.65% in 2022 and later dropped 9.44% in 2025.
  • Tracing WST's Leases over 5 years: stood at $104.4 million in 2022, then fell by 4.98% to $99.2 million in 2023, then grew by 5.34% to $104.5 million in 2024, then increased by 11.96% to $117.0 million in 2025, then decreased by 5.81% to $110.2 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $110.2 million, $117.0 million, and $97.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.